### The Future Role of the Cardiologist in Extracardiac Intervention: Carotid and Renal Arteries

**G.Biamino** 



#### **Clinical and Interventional Angiology**

**University of Leipzig Heart Center** 

### Undefined

Controversial

### Undefined

#### The Expression

### "Vascular Interventionalis

does not exsist.


### Controversial

- -Who should decide when the pat. has to be treated ?
- -Who should perform the intervention ?
- -Who should take care of the pat. during the follow-up?

# Main Question Do we really need an extension of cardiologist's interventional activities into the peripheral field ?



### Interventional Cardiologists beyond PCI: Multisite Endovascular Therapy



### Renal Carotid

### Pelvic Subinguinal

### The first PTRA, 07.12. 1977


#### Treatment of Renovascular Hypertension by Transluminal Renal Artery Dilatation

FELIX MAHLER, M.D.; ALEX KRNETA, M.D.; and MICHAEL HAERTEL, M.D.

Inselspital; Bern, Switzerland

A 50-year-old woman was admitted to hospital in 1977 because of hypertension. In July her blood pressure was 240/120 mm Hg, and methyldopa therapy, 750 mg daily, was started. At examination her blood pressure was 140/100 mm Hg, and a high-pitched bruit was heard in the left upper abdominal quadrant. Arteriography revealed severe stenosis in the middle third of the left renal artery and a string-of-beads appearance of the distal right renal artery, suggesting intimal fibroplasia on the left and medial fibroplasia on the right side (4) (Figure 1a). Peripheral renin activity of 8.1 ng/ml - h was clearly higher than our normal standard (5), and the left-to-right ratio of the selective renal vcin renin of 1.90 lateralized the excess renin to the left side. On 7 December transluminal dilatation of the left renal artery was done under general anesthesia at the patient's request (Figure 1b). After dilatation, anticoagulation therapy

Reprinted from ANNALS OF INTERNAL MEDICINE Vol. 90, No. 1 January 1979. Printed in U.S.A.



### The Role of the Cardiologist Renal Stenosis



#### Andreas Grünzig 1975



### **Cosmetic or Clinically Relevant ?**





Atherosclerotic Renal Artery Stenosis--What are the Facts?

### **POOR DATA ON**

- Incidence
- Prevalence
- Progression

### Incidence of Renal Stenosis in Patients with CHD

**15** % of patients undergoing CABG a significant RAS > 50 % can be found (Heart Center Leipzig)

**19%** of patients (101/534) referred for coronary angiography with refractory hypertension (> 140/90 on two drugs) had RAS >70%. (Khosla et al., Cath.Card.Interv.2003,58:400-03)

### Incidence of Renal Stenosis in Patients with CHD

- In a cohort of 500 consecutive patients showing a relevant coronary disease
  - -20% had an undetected renal stenosis
  - in half of these cases the stenosis was considered critical

### 8-10 %

P.Rubino et al., Cardiovascular Clinic, Montevergine Mercogliano (AV)


#### Stent-angioplasty of RAS: Results - randomized trial stent vs PTA

	PTRA	PTRA/Stent
Number of patients	<b>42</b>	43
Primary success rate	57%	88%
Primary patency rate	29%	75%
Restenosis rate	48%	14%


Van den Ven et al.: Lancet 1999; 282-286


### **Stent-angioplasty of RAS**


#### Kaplan-Meier-curve: n = 364



Th. Zeller, 2002











What is the Problem Today??

Primary Success Rate
~100%
Restenosis Rate < 10%</li>
Complications rare



### Potential Indication for Renal Artery Revascularization

- Refractory/Resistant Hypertension
- Chronic Renal Insufficiency


Recurrent Flash Pulmonary Edema

### **FEW DATA**

Need for Use of ACEI

Unilateral Renal Artery Stenosis

### **NO DATA**



Results of Renal Artery Angioplasty/ Stenting in Hypertensives

 Accumulate data from 8 authors 349 patients with mean follow up 11 months

### Hypertension:

Unchanged	44%
Improved	<b>56%</b>
Cure	10%

Palmaz JVIR 1998;9:539-430

### Endovascular Treatment of RAS in Ischaemic Nephropathy



### **IMPROVED**

#### UNCHANGED

### **DETERIORATED** ??



Acute Deterioration in Renal Function after Angioplasty/ Stenting

Incidence of 10-20% in patients with ischemic nephropathy Possible aetiologies:

-iodinated contrast nephropathy

-procedure related arterial trauma(e.g dissection)

-cholesterol atheroembolization

Sos, ISET 2004

GREAT Study 6-Month QCA Data					
	Bare	SES			
	Mean <u>+</u> SD	Mean <u>+</u> SD	P-value		
	N=41 (79%)	N=45 (85%)			
Reference vessel diameter	5.58 ± 0.81 mm	5.52 ± 0.73	0.74		
Diameter	$23.9 \pm 22.89$	$18.7 \pm 15.58$	0.39		
My conclusion :					
NO differences, waste of time and money					
diameter (MLD)	(0.2 - 6.8)	(1.6 – 6.1)			
In-stent restenosis	6(14.3%)	3 (6.7%)	0.30		
(> 50%)	0(14.370)	3 (0.7 70)	0.30		
Late Loss	0.92	0.62	0.21		



### **Renal Artery Angioplasty**

•No reliable noninvasive test to assess the functional severity of the renal stenosis

•1/3 improves, 1/3 unchanged, 1/3 further deterioration
(BP + Renal function)

99 000 procedures,

in 2003 (WW)

- US : 60 000
- EU : 30 000
- ROW: 10 000

• No reliable noninvasive testing to predict which patient might benefit from renal artery

•Very little is known on pathophysiology of renal artery stenosis revascularisation.

With permission of Bernard De Bruyne


# How can we prevent an excess of


#### **OCULO-STENOTIC REFLEXES IN RAS??**

#### **!!! WE NEED EVIDENCE BASED DATA !!!**


### The Role of the Cardiologist in Carotid Artery Stenting (CAS)

### First FDA Approval Sept.10<sup>th</sup> 2004





### Current principles of neuroprotection



### **Filter Wire - Animation**



### Filter Embolic Protection Devices




### **Restenosis post TEA**






### Restenosis post TEA







### **Operational Steps**




Device introduction, positioning, balloons inflation




Lesion pre-dilatation




Debris removal by bood aspiration




Stent deployment




Debris removal by bood aspiration



**Stent post-dilatation** 




Debris removal by bood aspiration



**Device removal** 

### Step by Step Carotid Stenting using the Mo.Ma Protection Device I






### Step by Step Carotid Stenting using the Mo.Ma Protection Device II








### Step by Step Carotid Stenting using the Mo.Ma Protection Device III






# Step by Step Carotid Stenting using the Mo.Ma Protection Device IV







#### Step by Step Carotid Stenting using the Mo.Ma Protection Device V



#### Debris Following Carotid Stenting (MoMa-Device)



#### MOMA In-Hospital Outcome

Death	during procedure	0
	in-hospital	0
Major Stroke	during procedure	0
	in-hospital	0
Minor Stroke	during procedure	2 (1.25%)
	in-hospital	<b>2 (1.25%)</b> 1 (intracr. bleeding)
TIA	during procedure	5 (3.2%)
	in-hospital	3 (1.9%)

**Primary Endpoint** 

(Death, Stroke at discharge)



SAPPHIRE STUDY Randomized Patients (n : 307) 30-Day Event			
DEATH;STROKE	CAS	CEA	
AMI	N : 156	N : 151	
Global	5.8 %	12.6 %	
Symptomatic	4.2 %	(15.4 %)	
Asymptomatic	6.7 %	11.2 %	


#### Personal Summary of CAS-Studies at EuroPCR 2003

- European Carotid High-Risk Study
- Mo.Ma. Registry,
- ARCHeR,
- SAPPHIRE,

# Bea DEATH < 0.2%</li> Sec MAJOR STROKE < 0.5%</li> MINOR STROKE 3.5 - 4.0 %


#### **World Wide Carotid Procedures**

#### Morgan Stanley, BSC, estimates



#### **Carotid Artery Stenting (CAS)**

# Different sources of data indicate



of CAS are performed by cardiologists



#### **Carotid Artery Stenting (CAS)**


Prescriptions for a Disaster


 Just do it
 Learn by doing
 Treatment of angiographic pictures

#### "SENSE OR NON-SENSE" of PROTECTION DEVICES

# The new nightmare of renal stenting

#### "Nonsense" of filter-wires





Which segmental branch?

Courtesy of A.Cremonesi



#### **Open Questions**

- Wich amount of embolic material may provoke a relevant deterioration of the renal function in pts. with creatinine
  - -<1.1 mg/dl
  - 1.1-1.8 mg/dl
  - -> 2.0 mg/dl





#### **Open Questions**

 Within wich time frame should we expect a deterioration of the renal fuction after embolization

**NO ANSWER** 

- Hours ?

- Days ?

- Months ?






#### **Open Questions**

• We do not have any data indicating that using the new low profile systems and direct stentingtechnique the amount of collected debris remains constant ????



#### **Technical Improvement : The Coronary Technique**




#### Case Example




V.P. 010518\_10

#### Case Example




V.P. 010518\_7

#### Case Example



V.P. 010518\_7.1

#### Case Example




V.P. 010518\_8

#### Case Example



V.P. 010518\_9

#### Case Example





Die perkutane transluminale Rekanalisation chronischer Arterienverschlüsse mit einer neuen Dilatationstechnik


Andreas Grüntzig



Verlag Gerhard Witzstrock · Baden-Baden · Köln · New York


# First Peripheral PTA in Zürich 1971

At this time in 1977 he had already performed nearly 200 peripheral interventions before he abandoned the field starting the coronary adventure.



Die perkutane transluminale Rekanalisation chronischer Arterienverschlüsse mit einer neuen Dilatationstechnik

Andreas Grüntzig



Verlag Gerhard Witzstrock · Baden-Baden · Köln · New York

Preface:

"I am convinced that percutaneous transluminal angioplasty represents a real expansion of our therapeutic possibilities.....The advantage of this easy, safe, and cost reducing technique is evident....we have to evidentiate its value on the basis of credible scientific data, analyzing indication, acute and long term results ."

Walter Siegenthaler, Zürich 1977